

Clinical Policy Title:	infliximab-abda
Policy Number:	RxA.744
Drug(s) Applied:	Renflexis®, Remicade®
Original Policy Date:	04/18/2022
Last Review Date:	3/15/2024
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Crohn's Disease (must meet all):

- 1. Diagnosis of Crohn's disease CD;
- 2. Prescribed by or in consultation with a gastroenterologist;
- 3. Member meets one of the following (a or b):
 - a. Trial and failure of ≥ 3-month of at least one (1) conventional systemic therapy (e.g., azathioprine, 6-mercaptopurine [6-MP], methotrexate [MTX]) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
 - b. Trial and failure of corticosteroids (e.g., prednisone, methylprednisolone, budesonide), unless contraindicated or significant adverse effects experienced.
- 4. Trial and failure of at least one (1) of the following agents: Inflectra® or Avsola® unless contraindicated or clinically significant adverse effects are experienced;

Approval Duration

All Lines of Business (except Medicare): 12 months

B. Ulcerative Colitis (must meet all):

- 1. Diagnosis of Ulcerative Colitis;
- 2. Prescribed by or in consultation with a gastroenterologist;
- 3. Documentation of a Mayo Score ≥ 6;
- 4. Member meets one of the following (a or b):
 - a. Trial and failure of ≥ 3 months of at least one conventional agent (azathioprine, 6-mercaptopurine, aminosalicylate), unless contraindicated or clinically significant adverse effects are experienced;
 - b. Trial and failure of corticosteroids (e.g., prednisone, methylprednisolone, budesonide) unless contraindicated or significant adverse effects experienced;
- 5. Trial and failure of at least one (1) of the following agents: Inflectra® or Avsola® unless contraindicated or clinically significant adverse effects are experienced;

Approval Duration

All Lines of Business (except Medicare): 12 months

C. Rheumatoid Arthritis (must meet all):

- 1. Diagnosis of Rheumatoid Arthritis (RA);
- 2. Prescribed by or in consultation with a rheumatologist;
- 3. Trial and failure of ≥ 3-months of at least one conventional systemic therapy (methotrexate [MTX],

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.



sulfasalazine, leflunomide, hydroxychloroquine), unless contraindicated or clinically significant adverse effects are experienced;

4. Trial and failure of at least one (1) of the following agents: Inflectra® or Avsola® unless contraindicated or clinically significant adverse effects are experienced.

Approval Duration

All Lines of Business (except Medicare): 12 months

D. Ankylosing Spondylitis (must meet all):

- 1. Diagnosis of active ankylosing spondylitis (AS);
- 2. Prescribed by or in consultation with a rheumatologist;
- 3. Trial and failure of at least two (2) non-steroidal anti-inflammatory drugs (NSAIDs), each used for at ≥ 4 weeks unless contraindicated or clinically significant adverse effects are experienced;
- 4. Trial and failure of at least one (1) of the following agents: Inflectra® or Avsola® unless contraindicated or clinically significant adverse effects are experienced;

Approval duration

All Lines of Business (except Medicare): 12 months

E. Psoriatic Arthritis (must meet all):

- 1. Diagnosis of Psoriatic Arthritis PsA;
- 2. Prescribed by or in consultation with a dermatologist or rheumatologist;
- 3. Trial and failure of at least one (1) of the following agents: Inflectra® or Avsola®, unless contraindicated or clinically significant adverse effects are experienced;

Approval duration

All Lines of Business (except Medicare): 12 months

F. Plaque Psoriasis (must meet all):

- 1. Diagnosis of chronic-severe PsO as evidenced by involvement of one of the following (a or b):
 - a. ≥ 10% of total body surface area;
 - b. Hands, feet, scalp, face, or genital area.;
- 2. Prescribed by or in consultation with a dermatologist or rheumatologist;
- 3. Trial and failure of at least ≥ 3 month at least one (1) conventional systemic therapy (methotrexate [MTX], cyclosporin, acitretin) or phototherapy (psoralen plus ultraviolet A light [PUVA]), unless contraindicated or clinically significant adverse effects are experienced;
- 4. Trial and failure of at least one (1) of the following agents: Inflectra® or Avsola® unless contraindicated or clinically significant adverse effects are experienced;

Approval duration

All Lines of Business (except Medicare): 12 months

II. Continued Therapy Approval

A. All Indications in Section I (must meet all):

1. Member is currently receiving or has been treated with this medication within the past 90 days, excluding manufacturer samples.

Approval Duration

All Lines of Business (except Medicare): 12 months

References

Revised 10/2023 Page 2 of 4 v 2.0.01.1



- 1. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid Arthritis Classification Criteria. Arthritis and Rheumatism September 2010;62(9):2569-2581. Available at: https://pubmed.ncbi.nlm.nih.gov/20872595/. Accessed March 27, 2023.
- 2. Boulos P, Dougados M, MacLeod SM, et al. Pharmacological Treatment of Ankylosing Spondylitis. Drugs. 2005; 65: 2111-2127. Available at: https://pubmed.ncbi.nlm.nih.gov/16225367/. Accessed March 27, 2023.
- 3. Sandborn WJ. Crohn's Disease Evaluation and Treatment: Clinical Decision Tool. Gastroenterology 2014; 147: 702-705. Available at: https://pubmed.ncbi.nlm.nih.gov/25046160/. Accessed March 27, 2023.
- 4. Bernell O, Lapidus A, Hellers G. Risk Factors for Surgery and Postoperative Recurrence in Crohn's Disease. Annals of Surgery. 2000; 231(1): 38-45. Available at: https://pubmed.ncbi.nlm.nih.gov/10636100/. Accessed March 27, 2023.

Review/Revision History	Review/Revision Date	P&T Approval Date
RxA.592.Biologic_DMARDs was last reviewed and updated on 01/05/2022 and archived on 04/18/2022. For details, please refer to RxA.592.Biologics_DMARDs.	01/05/2022	04/18/2022
Drug specific policy for Renflexis® was created based on RxA.592.Biologics_DMARDs: 1. Initial Approval Criteria, I.A.5, I.B.5, I.C.5, I.D.5, I.E.5, I.F:4 was updated to include Trial and failure of at least one (1) of the following agents: Inflectra® or Avsola® unless contraindicated or clinically significant adverse effects are experienced. 2. Initial Approval Criteria, I.F.4: Updated trial and failure criteria to rephrase and include phototherapy (psoralen plus ultraviolet A light [PUVA]). 3. References were reviewed and updated.	02/11/2022	04/18/2022
Policy was reviewed: 1. Initial Approval Criteria, I.B.4: Updated to include new documentation criteria, Documentation of a Mayo Score ≥ 6. 2. Initial Approval Criteria, I.F.1: Updated diagnosis criteria from Diagnosis of PsO to Diagnosis of chronic-severe PsO as evidenced by involvement of one of the	03/27/2023	04/13/2023

© 2023 RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited.

Revised 10/2023 Page 3 of 4 v 2.0.01.1



 following (a or b): a. ≥ 10% of total body surface area; b. Hands, feet, scalp, face, or genital area 3. References were reviewed and updated. 		
Policy was reviewed.	10/19/2023	10/19/2023
Policy was reviewed: 1. Removed dose and age 2. Formatting changes	1/1/2024	10/19/2023
Policy reviewed: Removed: 1. At maximally tolerated doses 2. Language of bypassinf t/f of systemic tx if on prior DMARD tx.	3/15/2024	10/19/2023

Revised 10/2023 Page 4 of 4 v 2.0.01.1